期刊文献+

美国、欧盟和我国实施ICH Q12管理工具的比较研究 被引量:1

A comparative study on the implementation of ICH Q12 management tools in the United States,the European Union and China
原文传递
导出
摘要 针对药品批准后CMC变更管理,ICH Q12提出了批准后CMC变更分类、既定条件、批准后变更管理方案、产品生命周期管理文件等管理工具。美国、欧盟和我国在实施这些管理工具上有不同的做法。借鉴和参考美国、欧盟的实施经验,对于优化我国的CMC变更管理具有重要意义。本文对转变监管部门对药品批准后CMC变更管理的理念、对变更进行分类管理、优化变更管理工具提出建议。 For post-approval CMC Changes,ICH Q12 proposed management tools such as categorization of post-approval CMC changes,ECs,PACMP,and PLCM documents.The United States,the European Union and China have different approaches in implementing these management tools.It is of great significance to learn from and refer to the implementation experience of the United States and the European Union for optimizing China’s post-approval CMC change management.We hope to change the supervision department’s concept of post-approval CMC change management,manage changes by category,and optimize change management tools.
作者 孙冠男 张鼎衡 于飞 左金梁 周娣 颜久兴 SUN Guan-nan;ZHANG Ding-heng;YU Fei;ZUO Jin-liang;ZHOU Di;YAN Jiu-xing(Tianjin Vocational College of Bioengineering,Tianjin 300462,China;China Center for Food and Drug International Exchange,Beijing 100082,China;Pharmacy College,Tianjin Medical University,Tianjin 300070,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2023年第2期205-209,共5页 Chinese Journal of New Drugs
关键词 ICH Q12 管理工具 CMC变更 比较研究 优化 ICH Q12 management tools CMC changes comparative study optimization
  • 相关文献

参考文献6

二级参考文献45

  • 1徐立华,连潇嫣,张凌超,张宁.结合ICH Q12草案浅析药品生命周期管理的相关要求[J].中国新药杂志,2020,29(3):258-263. 被引量:11
  • 2于星.上市后药品再评价[J].医药导报,2006,25(12):1336-1338. 被引量:6
  • 3龚时薇,张亮,黄杰敏,詹学锋,姜卫,王成江.药品安全与风险管理[J].中国药房,2007,18(22):1687-1690. 被引量:45
  • 4ICH.GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS Q7(Current Step 4version )[S/OL].(2000-11-10)[2016-06-14].http://www.ich.org/ fileadminlPublie Web_SitellCH_ProductslGuidelineslQuality/Q7/ Step4/Q7_Guideline.pdf.
  • 5ICH.PHARMACEUTICAL QUALITY SYSTEM QIO (Current Step 4 version ) [SlOL].(2008-O6-O4)[2016-O6-14].http:llwww.ich.orgl fileadmin/Public_Web_ Site/IC H Products/Guidelines/Quality/ Q10/Step4/QlO_Guideline.pdf.
  • 6ICH. Final Concept Paper Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecyele Management[EB/OL].(2014- 07-28)[2016-06-14].http://www.ich.org/fileadmin/PublieWeb_ Site/ICH_Products/Guidelines/Quality/Q12/Q12_Final_Concept_ Paper_July_2014.pd.
  • 7EMA. COMMISSION REGULATION (EC) No 1234/2008d concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products [S/OL]. (2008-11-24)[2016-06-14].http://ec.europa. eu/health/files/eudralex/vol-1/reg_ 20081234 cons_2012-11- 02/reg_2008_1234_cons_2012-11-02_en.pdf.
  • 8USA.21 USC 356a: Manufacturing changes[S/OL]. (2016-01-30) [2016-06-14].http://uscode.house.govviewxhtml?req=granuleid: USC-prelim-title21-section356a&num=O&edition=prelim. FDA.
  • 9CODEOF FEDERAL REGULATIONSTITLE 21 314.70(10) [S/OL].(2014-Ol-O1)[2016-O6-14].http://www.gpo.gov/fdsys/pkg/ CFR-2014-title21-vol5/pdf/CFR-2014-title21-vol5.pd.
  • 10EMA. Guidelines on the details of the various categories of variations, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products and on the documentation to be submitted pursuant to those procedures[S/OL]. (2013-02-08) [2016-06-14]. http://ec.europa.eu/health/files/endralex/vol-1/c_2013_223/c_2013_ 2804_en.pdf. FDA.

共引文献31

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部